Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2011

 
 
 

Ceftobiprole  

  • Ambrosch A, Haefner S, Jude E, Lobmann R. Diabetic foot infections: Microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus. Int Wound J. 2011; 8(6): 567-577.
  • Bazan JA, Martin SI, Kaye KM. Newer Beta-lactam Antibiotics: Doripenem, Ceftobiprole, Ceftaroline, and Cefepime. Med Clin North Am. 2011; 95(4): 743-760.
  • Bérenger R, Bourdon N, Auzou M, Leclercq R, Cattoir V. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008. Med Mal Infect. 2011; 41(8): 405-409.
  • Bobba S, Ponnaluri VKC, Mukherji M, Gutheil WG. Microtiter plate-based assay for inhibitors of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(6): 2783-2787.
  • Cereda RF, Azevedo HD, Girardello R, Xavier DE, Gales AC. Antimicrobial activity of ceftobiprole against Gram-negative and Gram-positive pathogens: Results from INVITA-A-CEFTO Brazilian study. Braz J Infect Dis. 2011; 15(4): 339-348.
  • Chahine EB, Nornoo AO. Ceftobiprole: The First Broad-Spectrum Anti-methicillin-resistant Staphylococcus aureus Beta-Lactam. J Exp Clin Med. 2011; 3(1): 9-16.
  • Eichenbaum G, Skibbe J, Parkinson A, Johnson MD, Baumgardner D, Ogilvie B, Usuki E, Tonelli F, Holsapple J, Schmitt-Hoffmann A. Use of enzyme inhibitors to evaluate the conversion pathways of ester and amide prodrugs: A case study example with the prodrug ceftobiprole medocaril. J Pharm Sci. 2011.
  • Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Majcherczyk P, Moreillon P. In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2011; 55(9): 3977-3984.
  • García MM. Ceftaroline and ceftobripol as new cephalosporines. Rev Cuba Farm. 2011; 45(3): 318-320.
  • Goo K-S, Sim T-S. Designing new β-lactams: Implications from their targets, resistance factors and synthesizing enzymes. Curr Comput-Aided Drug Des. 2011; 7(1): 53-80.
  • Karlowsky JA, Adam HJ, DeCorby MR, Lagacé-Wiens PRS, Hoban DJ, Zhanel GG. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob Agents Chemother. 2011; 55(6): 2837-2846.
  • Kratzer C, Dungl C, Tobudic S, Karaca K, Kreischitz N, Graninger W. In vitro susceptibility of ceftobiprole, vancomycin and fosfomycin against recent clinical bloodstream isolates of methicillin-resistant Staphylococcus aureus in the General Hospital of Vienna. Clin Microbiol Infect. 2011; 17: S706.
  • Kresken M, Körber-Irrgang B, Läuffer J, Decker-Burgard S, Davies T. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: Evidence of a synergistic effect using time-kill methodology. Int J Antimicrob Agents. 2011; 38(1): 70-75.
  • Kriegeskorte A, Ballhausen B, Idelevich EA, Köck R, Karch H, Peters G, Becker K. Occurrence of a newly described divergent mecA homologue with diagnostic impact in German clinical Staphylococcus aureus isolates. Int J Med Microbiol. 2011; 301: 7.
  • Lascols C, Legrand P, Mérens A, Leclercq R, Muller-Serieys C, Drugeon HB, Kitzis MD, Reverdy ME, Roussel-Delvallez M, Moubareck C, Brémont S, Miara A, Gjoklaj M, Soussy C-J. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: Proposition of zone diameter breakpoints. Int J Antimicrob Agents. 2011; 37(3): 235-239.
  • Lee M-R, Huang Y-T, Liao C-H, Lai C-C, Lee P-I, Hsueh P-R. Bacteraemia caused by Weissella confusa at a university hospital in Taiwan, 1997-2007. Clin Microbiol Infect. 2011; 17(8): 1226-1231.
  • Nerandzic MM, Donskey CJ. Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice. Antimicrob Agents Chemother. 2011; 55(5): 2174-2177.
  • Reygaert WC. Ceftobiprole: An emerging therapeutic option for resistant and complicated infections. Clin Med Insights Ther. 2011; 3: 57-66.
  • Ríos Dueñas E, Rodríguez-Avial I, Picazo JJ. In vitro activity of ceftobiprole and seven other antimicrobial agents against invasive Streptococcus pneumoniae isolates in Spain. Eur J Clin Microbiol Infect Dis. 2011; 30(12): 1621-1625.
  • Rizvi MW, Shujatullah F, Malik A, Khan HM. Ceftobiprole-A novel cephalosporin to combat MRSA. East J Med. 2011; 16(1): 1-8.
  • Roberts JA, Kirkpatrick CMJ, Lipman J. Monte Carlo simulations: Maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011; 66(2): 227-231.
  • Rossolini GM, Dryden MS, Kozlov RS, Quintana A, Flamm RK, Läuffer JM, Lee E, Morrissey I. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: The CLASS study. J Antimicrob Chemother. 2011; 66(1): 151-159.
  • Saleh Mghir A, Dinh A, Dumitrescu O, Lina G, Boutrad Y, Vandenesch F, Etienne J, Crémieux AC. Ceftobiprole efficacy in vitro on Panton-Valentine leukocidin production and in vivo in a rabbit community-associated methicillin-resistant Staphylococcus aureus osteomyelitis model. Clin Microbiol Infect. 2011; 17: S278.
  • Şensoy G. New cephalosporins. Cocuk Enfeksiyon Derg. 2011; 5(SUPPL. 1): 95-98.
  • Tobudic S, Poeppl W, Kratzer C, Vychytil A, Burgmann H. Comparative in vitro antimicrobial activity of vancomycin, teicoplanin, daptomycin and ceftobiprole in four different peritoneal dialysis fluids. Eur J Clin Microbiol Infect Dis. 2011; 1-8.
  • Walkty A, Adam HJ, Laverdière M, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: Results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis. 2011; 69(3): 348-355.
  • Wendland T, Daubner B, Pichler WJ. Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin. Br J Clin Pharmacol. 2011; 71(2): 297-300.
  • Xiong L-L, You L, Liu J-J, Li D-H. A novel broad-spectrum cephalosporin ceftobiprole. Chin J Antibiot. 2011; 36(9): 641-650.
  • Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother. 2011; 66(2): 343-349.
 

51st Interscience Congress on Antimicrobial Agents and Chemotherapy ICAAC, September 2011, Chicago, United States of America

  • E-118 / Comparison of In Vitro Activity of Ceftobiprole (BPR) with Ceftriaxone (CRO), Ceftazidime (TAZ), and Cefepime (FEP) Against Isolates of Rapidly Growing Microbacteria (RGM) and Nocardia (NOC). Wallace Jr RJ, Brown-Elliot BA, Kriel K, Martin T, Bridge L, Vasireddy R.
  • E-1335 / Investigating Ceftobiprole (Cef) Alone and in Combination with Daptomycin (Dap), Linezolid (Lin) and Vancomycin (Van) Against Methicillin-Resistant Staphylococcus aureus (MRSA) in an In Vitro Infection Model. Alkurdi N, Kumar A, Ariano R, Zelenitsky S.
  • K-1415 / New Cephalosporins against Gram-Positive and Gram-Negative Bacteria Have No Significant Ecological Impact on the Human Intestinal Microflora. Rashid M, Weintraub A, Nord C.
 

21st European Congress of Clinical Microbiology and Infectious Diseases ECCMID 27th International Congress of Chemotherapy ICC, May 2011, Milan, Italy

  • P-1068 / Ceftobiprole efficacy in vitro on Panton-Valentine leukocidin production and in vivo in a rabbit community-associated methicillin-resistant Staphylococcus aureus osteomyelitis model.  Saleh Mghir A, Dinh A, Dumitrescu O, Lina G, Boutrad Y, Vandenesch F, Etienne J, Crémieux AC.
  • R-2365 / In vitro susceptibility of ceftobiprole, vancomycin and fosfomycin against recent clinical bloodstream isolates of methicillin-resistant Staphylococcus aureus in the General Hospital of Vienna. Kratzer C, Dungl C, Tobudic S, Karaca K, Kreischitz N, Graninger W.
 

Isavuconazole

  • Badali H, De Hoog GS, Mohseni S, Meis JF. Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist. Mycoses. 2011; 54: 163.
  • Badali H, De Hoog GS, Sudhadham M, Meis JF. Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist. Med Mycol. 2011; 49(8): 819-824.
  • Girmenia CG. Azoles. Mycoses. 2011; 54: 25-26.
  • Girmenia C, Finolezzi E. New-generation triazole antifungal drugs: Review of the Phase II and III trials. Clin Invest. 2011; 1(11): 1577-1594.
  • Illnait-Zaragozí MT. Antifungal susceptibility and genetic characterization of Cuban Cryptococcus strains. Mycoses. 2011; 54: 170.
  • Lackner M, De Hoog GS, Geersten E, Verweij PE, Klaassen C, Meis JF. In vitro, species-specific, antifungal susceptibility patterns of all currently available systemic antifungal and Scedosporium. Mycoses. 2011; 54: 171.
  • Najafzadeh MJ, De Hoog GS, Klaassen CH, Meis JF. In vitro activity of eight antifungal drugs against 116 Exophiala species recovered from wet environments, coldblooded water animals and rare human cases. Mycoses. 2011; 54: 174.
  • Pitman SK, Drew RH, Perfect JR. Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. Expert Opin Emerg Drugs. 2011; 16(3): 559-586.
  • Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: Assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis. 2011; 71(4): 370-377.
  • Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses. 2011; 54(5): e583-e589.
  • Türel O. Newer antifungal agents. Expert Rev Anti-Infect Ther. 2011; 9(3): 325-338. 
 

Research

51st Interscience Congress on Antimicrobial Agents and Chemotherapy ICAAC, September 2011, Chicago, United States of America

  • A2-572 / Pharmacokinetics and Safety of the Novel Sulfactam Antibiotic BAL30072 after Single Ascending Dose Infusions in Healthy Volunteers. Schmitt-Hoffmann A, Roos B, Maares J, Sauer J, Spickermann J, Meyer I, Kaufhold A.
  • F1-145 / BAL30072: A Novel Monocyclic Sulfactam Antibiotic - Preclinical Pharmacokinetic Properties. Schmitt-Hoffmann A, Gebhardt K, Wind M, Hargreaves P, Klauer D, Brendle A, Serafyn A, Schlaefle C, Grunwald H, Bucher C, Spickermann J.
  • F1-146 / BAL30072: A Novel Monocyclic Sulfactam Antibiotic - Preclinical Safety Properties.  Schmitt-Hoffmann A, Bucher C, Spickermann J, Urwyler H.
  • E-722 / Activity of the Novel Sulfactam BAL30072, Alone and in Combination with Meropenem, Against Diverse Gram-Negative Isolates Carrying NDM-1 Beta-Lactamase Gene. Walsh TR, Weeks J, Toleman M, Howe R, Wootton M, Daniel V, Stubbings WJ, Jones ME.
  • E-737 / Bactericidal Activity of BAL30072 Compared to Other Agents against Multi-Resistant Gram-Negative Bacteria by Time-Kill. Pankuch GA, Clark C, Lin G, Stubbings W, Appelbaum PC,  Kosowska-Shick K.
  • F1-144 / Expression of Fe-Uptake Systems in Pseudomonas aeruginosa PAO1 and Susceptibility to the Siderophore Sulfactam BAL30072. Koehler T, Page MGP, Van Delden C.
 

21st European Congress of Clinical Microbiology and Infectious Diseases ECCMID 27th International Congress of Chemotherapy ICC, May 2011, Milan, Italy

  • P-1146 / Activity of the novel sulfactam BAL30072, alone and in combination with meropenem, against Enterobacteriaceae harbouring NDM-1 beta-lactamase. Walsh TR, Weeks J, Toleman M, Stubbings WJ, Page MGP, Jones ME.
  • P-1184 / In vitro activity of the siderophore sulfactam BAL30072 against meropenem non-susceptible Acinetobacter baumannii. Higgins PG, Stefanik D, Page MGP, Hackel M, Seifert H. 

 

American Association of Cancer Research AACR 102nd Annual Meeting 2011, April 2011, Orlando, United States of America

  • 1347 / BAL101553: An optimized prodrug of the microtubule destabilizer BAL27862 with superior antitumor activity. Pohlmann J, Bachmann F, Schmitt-Hoffmann A, Gebhardt K, Spickermann J, Nuoffer C, Biringer G, O'Reilly T, Pruschy M, Lane HA.
  • 743 / Development of tumor models resistant to the novel microtubule destabilizer BAL27862 (active moiety of the prodrug BAL101553). Bachmann F, Danel F, Burger K, Martinez R, Reinelt S, Page M, Steinmetz M, Lane HA.
 
Info